AstraZeneca ADCs

ADCs: AstraZeneca To Build Manufacturing Factory In Singapore

According to AstraZeneca, it will invest $1.5 billion in the construction of a manufacturing facility in Singapore for Antibody-Drug Conjugates (ADCs).

The biopharmaceutical giant announced this on Monday.

AstraZeneca aimed to start designing and construction of the manufacturing facility by the end of this year, with targeted operational readiness from 2029.

According to the company, ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.